You Tony J, Maxwell David S, Kogan Timothy P, Chen Qi, Li Jian, Kassir Jamal, Holland George W, Dixon Richard A F
Department of Medicinal Chemistry and Biophysics, Texas Biotechnology Corporation, Houston, Texas 77030, USA.
Biophys J. 2002 Jan;82(1 Pt 1):447-57. doi: 10.1016/S0006-3495(02)75409-X.
It is well established that integrin alpha 4 beta 1 binds to the vascular cell adhesion molecule (VCAM) and fibronectin and plays an important role in signal transduction. Blocking the binding of VCAM to alpha 4 beta 1 is thought to be a way of controlling a number of disease processes. To better understand how various inhibitors might block the interaction of VCAM and fibronectin with alpha 4 beta 1, we began constructing a structure model for the integrin alpha 4 beta 1 complex. As the first step, we have built a homology model of the beta 1 subunit based on the I domain of the integrin CD11B subunit. The model, including a bound Mg(2+) ion, was optimized through a specially designed relaxation scheme involving restrained minimization and dynamics steps. The native ligand VCAM and two highly active small molecules (TBC772 and TBC3486) shown to inhibit binding of CS-1 and VCAM to alpha 4 beta 1 were docked into the active site of the refined model. Results from the binding analysis fit well with a pharmacophore model that was independently derived from active analog studies. A critical examination of residues in the binding site and analysis of docked ligands that are both potent and selective led to the proposal of a mechanism for beta 1/beta 7 ligand binding selectivity.
整合素α4β1与血管细胞黏附分子(VCAM)和纤连蛋白结合,且在信号转导中发挥重要作用,这一点已得到充分证实。阻断VCAM与α4β1的结合被认为是控制多种疾病进程的一种方式。为了更好地理解各种抑制剂可能如何阻断VCAM和纤连蛋白与α4β1的相互作用,我们开始构建整合素α4β1复合物的结构模型。作为第一步,我们基于整合素CD11B亚基的I结构域构建了β1亚基的同源模型。该模型包括一个结合的Mg(2+)离子,通过一种专门设计的涉及约束最小化和动力学步骤的松弛方案进行了优化。将天然配体VCAM以及两种已证明可抑制CS-1和VCAM与α4β1结合的高活性小分子(TBC772和TBC3486)对接至优化模型的活性位点。结合分析的结果与一个独立源自活性类似物研究的药效团模型非常吻合。对结合位点残基的严格检查以及对强效且具选择性的对接配体的分析,促成了β1/β7配体结合选择性机制的提出。